AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
Leerink's David Risinger downgrades Bristol Myers to market perform and cuts his price target to $59, citing doubts on ...
City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
The Boston-area biotech hasn’t released any data over the last four weeks, but it still was able to pull off a stock sale ...
WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the ...
Epicrispr's epigenetic editor EPI-321 shows a 3% gain in muscle volume in FSHD patients at 6 months, alongside one case of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results